Compare Stocks: CNTB, ENTX, STTK, and ZURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$2.33	$2.26	$1.23 ▼ $3.82	$146.73M	-0.23	294,468 shs	84,564 shs
ENTX Entera Bio	$3.19 -0.2%	$2.33	$0.91 ▼ $4.20	$554.36M	1.38	1.11 million shs	43,443 shs
STTK Shattuck Labs	$7.91 +0.1%	$6.95	$0.97 ▼ $8.33	$791.86M	1.08	893,430 shs	62,722 shs
ZURA Zura Bio	$5.96 -0.6%	$5.36	$1.88 ▼ $7.44	$572.10M	-0.02	894,545 shs	247,523 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	-4.90%	-5.28%	+10.95%	-2.10%	+34.68%
ENTX Entera Bio	-8.07%	+2.57%	-18.62%	+161.48%	+61.11%
STTK Shattuck Labs	-1.99%	+3.13%	+12.22%	+32.33%	+674.51%
ZURA Zura Bio	-5.22%	+2.57%	+11.34%	+42.62%	+195.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$2.33	$2.26	$1.23 ▼ $3.82	$146.73M	-0.23	294,468 shs	84,564 shs
ENTX Entera Bio	$3.19 -0.2%	$2.33	$0.91 ▼ $4.20	$554.36M	1.38	1.11 million shs	43,443 shs
STTK Shattuck Labs	$7.91 +0.1%	$6.95	$0.97 ▼ $8.33	$791.86M	1.08	893,430 shs	62,722 shs
ZURA Zura Bio	$5.96 -0.6%	$5.36	$1.88 ▼ $7.44	$572.10M	-0.02	894,545 shs	247,523 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	-4.90%	-5.28%	+10.95%	-2.10%	+34.68%
ENTX Entera Bio	-8.07%	+2.57%	-18.62%	+161.48%	+61.11%
STTK Shattuck Labs	-1.99%	+3.13%	+12.22%	+32.33%	+674.51%
ZURA Zura Bio	-5.22%	+2.57%	+11.34%	+42.62%	+195.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	2.75	Moderate Buy	$7.43	220.20% Upside
ENTX Entera Bio	2.00	Hold	$9.00	167.22% Upside
STTK Shattuck Labs	3.00	Buy	$12.78	63.17% Upside
ZURA Zura Bio	2.86	Moderate Buy	$17.00	185.47% Upside

Current Analyst Ratings Breakdown

Latest CNTB, ENTX, STTK, and ZURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/12/2026	ZURA Zura Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$15.00 ➝ $22.00
8/12/2026	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $20.00
8/11/2026	STTK Shattuck Labs	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$18.00 ➝ $14.00
7/24/2026	STTK Shattuck Labs	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
7/20/2026	STTK Shattuck Labs	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/17/2026	ENTX Entera Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/9/2026	CNTB Connect Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$60K	2,434.84	N/A	N/A	$0.43 per share	5.40
ENTX Entera Bio	N/A	N/A	N/A	N/A	$0.04 per share	N/A
STTK Shattuck Labs	$1M	785.94	N/A	N/A	$2.10 per share	3.73
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.06 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	11/11/2026 (Estimated)
ENTX Entera Bio	-$11.44M	-$0.35	N/A	N/A	N/A	N/A	-147.19%	-103.22%	11/13/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)
ZURA Zura Bio	-$99.35M	-$1.13	N/A	N/A	N/A	N/A	-56.13%	-50.15%	11/12/2026 (Estimated)

Latest CNTB, ENTX, STTK, and ZURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/11/2026	Q2 2026	ZURA Zura Bio	-$0.1913	-$0.21	-$0.0187	-$0.21	N/A	N/A
8/7/2026	Q2 2026	ENTX Entera Bio	-$0.08	-$0.14	-$0.06	-$0.14	N/A	N/A
6/30/2026	Q2 2026	ZURA Zura Bio	N/A	-$0.21	N/A	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	2.37	2.37
ENTX Entera Bio	N/A	8.98	8.98
STTK Shattuck Labs	N/A	27.59	27.59
ZURA Zura Bio	N/A	12.90	12.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
ENTX Entera Bio	14.11%
STTK Shattuck Labs	58.74%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
ENTX Entera Bio	10.57%
STTK Shattuck Labs	8.79%
ZURA Zura Bio	12.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	62.97 million	48.74 million	Optionable
ENTX Entera Bio	20	173.83 million	155.46 million	Optionable
STTK Shattuck Labs	100	100.36 million	91.54 million	Optionable
ZURA Zura Bio	3	95.83 million	83.98 million	Optionable

CNTB, ENTX, STTK, and ZURA Headlines

Recent News About These Companies

Soligenix (NASDAQ:SNGX) and Zura Bio (NASDAQ:ZURA) Head-To-Head Survey

August 27 at 2:15 AM | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Sees Large Volume Increase - Here's Why

August 25 at 12:39 PM | marketbeat.com

Zura Bio (NASDAQ:ZURA) Shares Up 11.8% - What's Next?

August 24 at 12:40 PM | marketbeat.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | businesswire.com

Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 17, 2026 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Announces Quarterly Earnings Results

August 11, 2026 | marketbeat.com

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

August 11, 2026 | businesswire.com

Zura Bio (ZURA) Projected to Announce Earnings on Thursday

August 6, 2026 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Rating Increased to Sell at Wall Street Zen

August 1, 2026 | marketbeat.com

Stempoint Capital LP Makes New Investment in Zura Bio Limited $ZURA

July 30, 2026 | marketbeat.com

1,179,715 Shares in Zura Bio Limited $ZURA Purchased by EcoR1 Capital LLC

July 28, 2026 | marketbeat.com

Zura Bio Stock (NASDAQ:ZURAW), Analyst Ratings, Price Targets, Predictions

July 27, 2026 | benzinga.com

William Blair Starts Zura Bio (ZURA) at Outperform

July 14, 2026 | uk.finance.yahoo.com

Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist

July 9, 2026 | businesswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Zura Bio (ZURA)

July 9, 2026 | theglobeandmail.com

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

June 29, 2026 | finance.yahoo.com

Zura Bio (ZURA) Gets a Buy from Oppenheimer

June 13, 2026 | theglobeandmail.com

Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation

June 3, 2026 | finance.yahoo.com

Zura Bio Announces Board Resignation, Governance Stability Affirmed

May 22, 2026 | tipranks.com

Analysts Are Bullish on These Healthcare Stocks: Silence Therapeutics (SLN), Zura Bio (ZURA)

May 11, 2026 | theglobeandmail.com

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

May 7, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, ENTX, STTK, and ZURA Company Descriptions

Connect Biopharma NASDAQ:CNTB

$2.33 0.00 (0.00%)

As of 10:41 AM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Entera Bio NASDAQ:ENTX

$3.18 -0.01 (-0.16%)

As of 10:41 AM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Shattuck Labs NASDAQ:STTK

$7.90 +0.01 (+0.06%)

As of 10:42 AM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Zura Bio NASDAQ:ZURA

$5.96 -0.03 (-0.55%)

As of 10:42 AM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, ENTX, STTK, and ZURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, ENTX, STTK, and ZURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, ENTX, STTK, and ZURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, ENTX, STTK, and ZURA Company Descriptions

Connect Biopharma NASDAQ:CNTB

Entera Bio NASDAQ:ENTX

Shattuck Labs NASDAQ:STTK

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, ENTX, STTK, and ZURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, ENTX, STTK, and ZURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, ENTX, STTK, and ZURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, ENTX, STTK, and ZURA Company Descriptions

Connect Biopharma NASDAQ:CNTB

Entera Bio NASDAQ:ENTX

Shattuck Labs NASDAQ:STTK

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools